Doxorubicin News and Research

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

FISH technology accurate in measuring the HER-2 receptor in human breast tumors

20. November 2009 11:24

The debate on how to select patients who will respond best to costly drug treatments for aggressive breast cancer now favors fluorescence in situ hybridization (FISH) to measure the HER-2 receptor found in human breast tumors, according to a leading pathologist presenting at the Association for Molecular Pathology annual meeting. [More]

cb589363-95d8-48b5-b93d-447399d1a7e5|0|.0

Posted in: Device / Technology News | Women's Health News

Tags: Adjuvant Therapy, Breast Cancer, Cancer, Chemotherapy, Cyclophosphamide, DNA, Doxorubicin, Fluorouracil, Mammography, Oncology, Pathology

New radical approach to test chemo drugs for potential toxic effects

19. November 2009 02:25

Jackson Laboratory Professor Gary Churchill wants to change that. With a new two-year, $1 million grant from the National Cancer Institute, Churchill is launching a radical new approach to testing three chemotherapeutic drugs for potential toxic effects. [More]

c84a42b1-b80f-4fe7-93c5-00d675c6b98b|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Anemia, Bone, Bone Marrow, Cancer, Chemotherapy, Cyclophosphamide, Docetaxel, Doxorubicin

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

18. November 2009 10:31

Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March. [More]

a61a65ac-e150-48dc-bb4d-d91e79fc3c1c|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Abdominal Pain, Anemia, Anorexia, Anxiety, Arthralgia, Blindness, Bone, Cancer, Cell, Constipation, Cough, Dehydration, Diarrhea, Doxorubicin, Dyspnea, Edema, Headache, Heart Failure, Herpes, Herpes Zoster, Hypersensitivity, Insomnia, Liposome, Lymphoma, Multiple Myeloma, Nausea, Neuropathy, Neutropenia, Nursing, Oncology, Peripheral Neuropathy, Pneumonia, Thrombocytopenia, Ubiquitin, Vomiting

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

18. November 2009 09:14

CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer. [More]

22d7d56a-040a-4b79-b687-06869cbedf35|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Anemia, Cancer, Cell, Chemotherapy, Doxorubicin, Dysplasia, Epirubicin, Gastritis, Helicobacter pylori Infection, Investment, Leukemia, Oncology, Smoking, Stomach Cancer, Tobacco

CytRx reports financial results for the three months and nine months ended September 30, 2009

9. November 2009 09:17

CytRx Corporation, a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009. [More]

501b5920-8b6e-4819-adb5-ce67f9a54d60|0|.0

Posted in: Business / Finance

Tags: Arsenic, Brain, Breast Cancer, Cancer, Cell, Chromosome, Chronic Myeloid Leukemia, Doxorubicin, Gleevec, Investment, Kinase Inhibitor, Leukemia, Myeloid Leukemia, Oncology, Ovarian Cancer, Pancreatic Cancer, Retinoic Acid, Stroke

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

6. November 2009 07:38

ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. [More]

c33ab7fd-4a47-496c-ab34-49adcecd0d14|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Alopecia, Anemia, Arsenic, Bone, Brain, Breast Cancer, Cancer, Capecitabine, Cell, Cyclophosphamide, Doxorubicin, Gleevec, Lymphoma, Nausea, Neuropathy, Neutropenia, New Drug Application, Oncology, Soft Tissue Sarcoma, Testicular Cancer, Xeloda

Lovastatin-synthesizing enzyme successfully reconstituted

4. November 2009 00:15

Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin. [More]

5d7c402a-09b8-4203-a86b-b5e46a4d7bf5|0|.0

Posted in: Medical Science News | Pharmaceutical News

Tags: Antibiotic, Cholesterol, Doxorubicin, Erythromycin, Nanotechnology, Rapamycin, Tetracycline

Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients

2. November 2009 07:43

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with platinum-resistant and taxane-pretreated ovarian cancer. [More]

a79b5ea4-5265-4acd-870c-02b524f17df0|0|.0

Posted in: Drug Trial News | Women's Health News

Tags: Cancer, Doxorubicin, Gynaecology, Obstetrics, Oncology, Ovarian Cancer, Prostate Cancer

Bioengineers develop nano-delivery system for cancer therapy

2. November 2009 00:08

Going smaller could bring better results, especially when it comes to cancer-fighting drugs. [More]

f2c98467-e44f-4ee0-ba3d-da7a17117c4c|0|.0

Posted in: Device / Technology News | Medical Condition News

Tags: Cancer, Chemotherapy, Doxorubicin, E. coli, Nanoparticle

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

27. October 2009 09:50

Celsion Corporation and Yakult Honsha Co., Ltd. announced today that the first patient has been enrolled and treated in Japan as part of Celsion’s global Phase III ThermoDox HEAT trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. [More]

f34df816-ed4b-4bf1-808b-587e3ecf4cee|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Breast Cancer, Cancer, Chemotherapy, Doxorubicin, Drug Delivery, Hepatitis B, Hepatocellular Carcinoma, Liposome, Liver Cancer, Oncology, Radiation Therapy, Radiofrequency Ablation, Ultrasound

BioSphere submits an IDE to the FDA for its QuadraSphere Microsphere product

27. October 2009 09:07

BioSphere Medical, Inc. – the leader in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) application for a clinical trial for the use of BioSphere’s QuadraSphere® Microsphere product (QuadraSphere) to deliver the chemotherapeutic agent doxorubicin for the treatment of primary liver cancer. [More]

e09b8f2b-e699-4a07-943b-00e7841b7a09|0|.0

Posted in: Device / Technology News | Medical Condition News

Tags: Cancer, Catheter, Doxorubicin, Hepatocellular Carcinoma, Liver Cancer, Oncology, Transplant, Uterine Fibroid

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

22. October 2009 05:22

Cell Therapeutics, Inc. announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients. [More]

74b248a8-f0d4-4193-b507-b88acce24c57|1|5.0

Posted in: Drug Trial News | Medical Condition News

Tags: Anemia, Anthracycline, Breast Cancer, Cancer, Catheter, Cell, Chemotherapy, Congestive Heart Failure, Cough, Cyclophosphamide, Doxorubicin, Heart Failure, Hodgkin's Lymphoma, Hospital, Leukemia, Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma, Oncology, Prescription Drug, Rituximab, Thrombocytopenia, Vincristine

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

22. October 2009 01:40

Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma. [More]

f4f541c0-5bc7-444a-abff-37b6118c369f|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Abdominal Pain, Anemia, Anorexia, Anxiety, Arthralgia, Blindness, Bone, Cell, Constipation, Cough, Cyclophosphamide, Dehydration, Diarrhea, Doxorubicin, Dyspnea, Edema, Headache, Heart Failure, Herpes, Herpes Zoster, Hypersensitivity, Insomnia, Liposome, Lymphoma, Multiple Myeloma, Nausea, Neuropathy, Neutropenia, Nursing, Oncology, Pneumonia, Rituximab, Thrombocytopenia, Vincristine, Vomiting

Celsion completes patient enrollment in its global Phase III ThermoDox trial

21. October 2009 08:06

Celsion Corporation announced today that it has completed a critical regulatory step in the countries of China and Japan to rapidly enroll patients in its global Phase III ThermoDox trial for the treatment of Hepatocellular Carcinoma (HCC), also known as primary liver cancer. [More]

3298bbc5-7530-44ba-bb4b-cce4d14b3738|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Breast Cancer, Cancer, Chemotherapy, Doxorubicin, Drug Delivery, Hepatitis B, Hepatocellular Carcinoma, Liposome, Liver Cancer, Oncology, Radiation Therapy, Radiofrequency Ablation, Ultrasound

Delcath Systems completes its pivotal Phase III Metastatic Melanoma Trial enrollment

21. October 2009 07:07

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that its pivotal Phase III Metastatic Melanoma Trial has met its goal of 92 patients and is fully enrolled. [More]

bf22a5b8-1053-4f49-93c1-6c81f6f084ba|0|.0

Posted in: Drug Trial News

Tags: Cancer, Chemotherapy, Doxorubicin, Drug Delivery, Hepatocellular Carcinoma, Melanoma, Ocular Melanoma

<< Previous posts

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

Free!

Recent Comments

Twitter

Information

Doxorubicin News and Research

FISH technology accurate in measuring the HER-2 receptor in human breast tumors

New radical approach to test chemo drugs for potential toxic effects

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

CytRx reports financial results for the three months and nine months ended September 30, 2009

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

Lovastatin-synthesizing enzyme successfully reconstituted

Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients

Bioengineers develop nano-delivery system for cancer therapy

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

BioSphere submits an IDE to the FDA for its QuadraSphere Microsphere product

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Delcath Systems completes its pivotal Phase III Metastatic Melanoma Trial enrollment

Recent Articles

Free!

Recent Comments

Twitter

Information

Doxorubicin News and Research

Medical News Cloud

Recent Articles